NDA 50195, held by Apothecon. Oxacillin Sodium.
As of Nov 13, 2026, NDA 50195 (Oxacillin Sodium), held by Apothecon, was not approved, with 0 approved supplements and 0 published complete response letters.
| Oxacillin SodiumEQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · injectable;injection | Oxacillin Sodium | DiscontinuedReference drug |
| Oxacillin SodiumEQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · injectable;injection | Oxacillin Sodium | DiscontinuedReference drug |
| Oxacillin SodiumEQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · injectable;injection | Oxacillin Sodium | DiscontinuedReference drug |
| Oxacillin SodiumEQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · injectable;injection | Oxacillin Sodium | DiscontinuedReference drug |
| Oxacillin SodiumEQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · injectable;injection | Oxacillin Sodium | DiscontinuedReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
